Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.51 |
| ▸ | CTSS | P25774 | 4/20 | 0.50 |
| ▸ | CTSL | P07711 | 3/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 4/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | KYNU | Q16719 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10045788 | 1.00 | PPARA (0.51) | PPARACTSSCTSLITGB3ITGA2B | |
| SCHEMBL10045790 | 0.92 | CTSS (0.49) | PPARACTSSCTSLITGB3ITGA2B | |
| SCHEMBL15924778 | 0.92 | KYNU (0.53) | CTSSCTSLCTSBCTSKATM | |
| SCHEMBL15924777 | 0.92 | KYNU (0.53) | CTSSCTSLCTSBCTSKATM | |
| SCHEMBL5724195 | 0.89 | SYK (0.52) | CTSSCTSLITGB3ITGA2BCTSB | |
| SCHEMBL23455744 | 0.88 | ITGB3 (0.50) | PPARACTSSCTSLITGB3ITGA2B | |
| SCHEMBL23455745 | 0.88 | ITGB3 (0.50) | PPARACTSSCTSLITGB3ITGA2B | |
| SCHEMBL5724014 | 0.88 | ATM (0.50) | CTSSCTSLCTSBCTSKATM | |
| SCHEMBL7513292 | 0.87 | ITGB3 (0.53) | PPARACTSSCTSLITGB3ITGA2B | |
| SCHEMBL1199787 | 0.87 | ITGB3 (0.53) | PPARACTSSCTSLITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | PPARA 1332/4885CTSS 4539/4885CTSL 4757/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | PPARA 1332/4885CTSS 4539/4885CTSL 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.